BCL2 and hepatocellular carcinoma: In addition, matrine-derived compounds can inhibit the development of hepatocellular carcinoma by reducing the expression of Bcl-2, inducing cell cycle arrest, reducing the number of EpCAM and CD133 cells, and inhibiting the expression of CSC markers (163).